IFF Announces Further Evolution of its Board of Directors
27.2.2023 14:55:00 EET | Business Wire | Press release
IFF (NYSE: IFF) today announced the next phase of the evolution of its Board of Directors, to support the ongoing execution of the company’s strategic transformation and long-term financial vision.
Kevin O’Byrne, Chief Financial Officer and director of J Sainsbury Plc, has been appointed to join the IFF Board, effective March 10, 2023. O’Byrne is an established financial executive with decades of experience driving sustainable growth and overseeing transformation strategies for international consumer retail businesses. He brings to IFF a deep understanding of the consumer landscape and evolving expectations of CPG customers, which will be valuable to IFF as it continues to execute on its customer-centric and growth-focused strategy. O’Byrne will serve on the Board’s Audit, Innovation, and Transaction Committees.
IFF also announced that Edward (Ed) Breen and Matthias Heinzel, both of whom have served as directors and members of the Board’s Innovation Committee since 2021, have notified IFF of their respective decisions to retire from the Board. Breen and Heinzel will not stand for reelection at IFF’s 2023 Annual Meeting of Shareholders. In addition, Stephen Williamson, director since 2017 and a member of the Board’s Audit Committee, has notified IFF of his decision to retire from the Board effective March 10, 2023.
“On behalf of the entire Board, I would like to thank Ed, Stephen and Matthias for their many contributions to IFF,” said Dale Morrison, Chair of the IFF Board. “As directors, each has helped oversee the development of IFF’s refreshed growth strategy as we’ve become an even stronger partner for customers across the global value chain for consumer goods and commercial products. It has been an honor to work alongside these three leaders and I wish them all the best in their next chapters.”
“It has been a privilege to serve on the IFF Board as the company has established itself as the industry’s premier partner through the transformative combination of DuPont’s Nutrition and Biosciences business,” said Ed Breen, Director of the IFF Board. “Both the IFF Board and leadership team have taken strong action to position the company for long-term profitable growth and significant value creation, and I look forward to seeing all that IFF will accomplish in the future.”
“As we continue to evolve our Board of Directors, I am thrilled to welcome Kevin as an incoming director,” said Roger Ferguson, Incoming Chair of the IFF Board. “Kevin brings more than 30 years of retail and consumer goods experience to the IFF Board and a proven track record overseeing numerous multinational finance initiatives and successful business integrations. I am confident that his expertise and international perspective will be critical as we capture new growth opportunities, execute on our productivity initiatives and optimize our portfolio.”
O’Byrne is responsible for the finance, strategy, property, procurement and investor relations functions at J Sainsbury Plc, the second largest retailer in the United Kingdom. He will be retiring from Sainsbury's on March 4, 2023. Prior to joining J Sainsbury Plc, he served as Chief Executive Officer of Poundland Group Plc and held various leadership positions at Kingfisher Plc, including Divisional Director UK, China and Turkey, as well as Chief Executive Officer of B&Q UK & Ireland and Group Finance Director.
O’Byrne sits on the Board of Centrica Plc, the leading energy supply and in-home servicing provider in the UK and Ireland. He has chaired the Audit and Risk Committee since May 2019 and is the Senior Independent Director (SID). O’Byrne sat on the board of Land Securities Group Plc, the UK’s largest listed real estate group, for nine years where he chaired the Audit Committee and was SID.
“I am thrilled to join the IFF Board during such an exciting time for the company,” said Kevin O’Byrne, Incoming IFF Director. “IFF continues to lead the industry in delivering innovative solutions that meet the needs of today’s customers, and the company has a clear opportunity to realize its full potential. I look forward to partnering with Roger and the rest of the Board to help IFF become an even stronger industry leader, while driving sustainable, profitable growth.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.
© 2023 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005174/en/
Contact information
Media Relations:
Paula Heinkel
332.877.5339
Media.request@iff.com
Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
